ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms

Respiratory Tract Infections Clinical Trial

— ADEQUATE  

Official title:

ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04547556
• Other study ID #: WP4b - adults
• Status: Terminated
• Phase: N/A
• Start date: October 25, 2021
• Est. completion date: May 21, 2022

Study information

• Verified date: November 2021
• Source: UMC Utrecht
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the impact of rapid diagnostic testing of patients with Acute Respiratory Tract Infection (ARTI) at the emergency department, on (1) hospital admission rates and (2) antimicrobial prescriptions (days of treatment) and (3) the non-inferiority in terms of clinical outcome. Geographical and seasonal variation will be assessed on a real time basis including pathogens of public health interest. The impact will be stratified within age groups and risk factors in order to determine the long-term clinical, public health and economic determinants for the integration of diagnostics in a global and sustainable perspective.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 185
• Est. completion date: May 21, 2022
• Est. primary completion date: May 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adults (=18 years old) presenting to the Emergency Room with an acute illness (present for 14 days or less) with cough, and with at least 1 other lower respiratory tract

symptom or clinical sign at physical examination:

• Sputum production,
• Breathlessness,
• Chest discomfort or chest pain,
• Wheeze,
• Crackles,
• Self-reported dystermia or documented fever;
• Documented hypoxemia (adjusting definition for chronic oxygen therapy users, method of measurement) and no alternative explanation (infection, such as sinusitis; other, such as asthma).

2. Managing medical team considers:

1. to treat patient with antibiotics and/or to hospitalize patient AND

2. that the rapid syndromic diagnostic test result can be awaited up to a maximum of 4 hours before the decision to discharge the patient or to initiate antibiotic therapy.

Exclusion Criteria:

1. Development of ARTI more than 48 hours after hospital admission (hospital acquired);

2. Patients with cystic fibrosis;

3. Less than 14 days since the last episode of respiratory tract infection;

4. Pregnancy (confirmed by pregnancy test) and breastfeeding;

5. Any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator would preclude safe completion of the study or constrain endpoints assessment such as major systemic diseases or patients with short life expectancy;

6. Inability to obtain informed consent from a competent patient. Based on standard of care microbiological diagnosis and thoracic imaging (when

indicated):

7. Radiologically confirmed acute lobar pneumonia;

8. Known or suspected Pneumocystis jirovecii pneumonia or active tuberculosis;

9. Alternative noninfectious diagnosis that explains clinical symptoms (pulmonary embolism, alveolar hemorrhage, acute heart failure, lung cancer).

Related Conditions & MeSH terms

• Communicable Diseases
• Emergencies
• Infections
• Respiratory Tract Infections

Intervention

Diagnostic Test:
• BioFire
A molecular rapid syndromic testing platform, using the following panels: BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus) BioFire FilmArray Pneumonia Panel plus (PP)

Locations

Country	Name	City	State
Germany	University Hospital Schleswig-Holstein	Lübeck

Sponsors (2)

Lead Sponsor	Collaborator
UMC Utrecht	BioMérieux

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Days alive out of hospital (superiority endpoint)		Day 1 - Day 14
Primary	Days on Therapy (DOT) with antibiotics (superiority endpoint)		Day 1 - Day 14
Primary	Adverse outcome (non-inferiority safety endpoint)	For initially non-admitted patients: any admission or death; For initially hospitalized patients: any readmission, ICU admission >= 24 hours after hospitalization, or death	Day 1 - Day 30
Secondary	Direct costs and indirect costs within 30 days after enrolment.	Cost of healthcare within 30 days after enrolment, including hospital and ICU days, utilisation of non-hospital services and cost of anti-infective and concomitant medication; Cost of workdays lost within 30 days, including days for childcare	Day 1 - Day 30
Secondary	Quality of life as determined by EQ5D-5L (or suitable alternative for age), days away from work if applicable, and healthcare utilisation on day 1, 14, and 30 after enrolment.	Quality of life as determined by EQ5D-5L (or suitable alternative for age), days away from work if applicable, and healthcare utilisation on day 1, 14, and 30 after enrolment.	Day 1, 14, 30
Secondary	Microbiological results obtained as standard of care and with the diagnostic intervention	Proportion of participants with an identified respiratory pathogen in both study groups on randomisation day samples.	Day 1
Secondary	Empirical antibiotics based on antimicrobial agent categories	Proportion of participants on non-first-line anti-infective regimens (as defined by local guidelines)	Day 1 - Day 14
Secondary	Antibiotic type switches and de-escalation based on antimicrobial agent categories	Time to de-escalation and time to stop of anti-infective therapy	Day 1 - Day 14
Secondary	Detection of antimicrobial resistance (carriage or infection) related to the diagnostic intervention results compared to standard of care and impact on antimicrobial stewardship guidelines and prevention of hospital acquired infections.	Proportion of hospitalised participants with detection of cephalosporin-, carbapenem- or chinolone-resistant Enterobacteriaceae on any standard of care samples >7 days after randomisation	>7 days after randomisation
Secondary	Impact on decisions regarding isolation measures related to test result.	Hours in individual or cohort isolation in hospitalised participants	Day 1 - Day 30